Atlas Trials

Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

Clinical trial NCT04124731 · UNKNOWN

Trial details

NCT number
NCT04124731
Sponsor
Shanghai Chest Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
CarcinomaNon-small Cell Lung Cancer
Start date
2019-10-01
Primary completion
2021-04-01
Enrollment
98

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.